Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

Clinical trial NCT02661282 · COMPLETED

Trial details

NCT number: NCT02661282
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Cytomegalovirus Positive Glioblastoma Gliosarcoma Malignant Glioma Recurrent Brain Neoplasm Recurrent Glioblastoma

Start date: 2016-06-01
Primary completion: 2022-02-23
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.